Anaverse™ Glenoid System and Its Instrumentation

NCT05215600 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-04-08

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to confirm safety, performance and clinical benefits of the Anaverse™ Glenoid System and its instrumentation by analysis of standard scoring systems, radiographs and adverse event records.

Conditions

  • Rotator Cuff Injuries
  • Shoulder Pain
  • Arthropathy
  • Arthroplasty Complications

Interventions

DEVICE

Anaverse Shoulder System

Reverse Shoulder Arthroplasty

Sponsors & Collaborators

  • Zimmer Biomet

    lead INDUSTRY

Principal Investigators

  • Hassan Achakri · Zimmer Biomet

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-06
Primary Completion
2024-04-23
Completion
2024-04-23

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05215600 on ClinicalTrials.gov